Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2411 to 2420 of 2683 total matches.

Smallpox Vaccine

   
The Medical Letter on Drugs and Therapeutics • Jan 06, 2003  (Issue 1147)
) FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS 1 Vaccination — Smallpox ...
Because of concerns about the possibility of bioterrorism involving smallpox, the US government is reinstituting smallpox vaccination (https://www.cdc.gov/smallpox/; www.idsociety.org/bt/toc.htm). Vaccination is currently expected to proceed in three phases: the military and hospital smallpox response teams first, other health care workers, police and firefighters second, and the general public in the third phase. Except for the military, vaccination will be...
Med Lett Drugs Ther. 2003 Jan 6;45(1147):1-3 |  Show IntroductionHide Introduction

Alendronate and Risedronate

   
The Medical Letter on Drugs and Therapeutics • Apr 25, 2005  (Issue 1207)
% of the alendronatetreated women. 1 After 5 years, placebo-treated patients were discharged from the study. Patients ...
A 10-year study of daily oral alendronate (Fosamax) and a 7-year study of daily oral risedronate (Actonel) indicate that both drugs maintained increases in bone mineral density (BMD) and decreases in markers of bone remodeling throughout the study period. Both drugs are now more commonly taken once weekly. Available data are insufficient to compare fracture rates with alendronate and risedronate, and fracture rates are considered the most important endpoint in osteoporosis studies. Recent reports of severe pain and jaw osteonecrosis with these drugs are disturbing.
Med Lett Drugs Ther. 2005 Apr 25;47(1207):33-5 |  Show IntroductionHide Introduction

Dasatinib (Sprycel) for CML and Ph+ ALL

   
The Medical Letter on Drugs and Therapeutics • Jan 15, 2007  (Issue 1252)
of CML, was approved by the FDA in 2001. 1 It is now the standard first-line treatment for all stages ...
Dasatinib (Sprycel - Bristol-Myers Squibb), an inhibitor of multiple tyrosine kinases, has been approved by the FDA for second-line treatment of chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adults.
Med Lett Drugs Ther. 2007 Jan 15;49(1252):6-7 |  Show IntroductionHide Introduction

Eculizumab (Soliris) for Paroxysmal Nocturnal Hemoglobinuria

   
The Medical Letter on Drugs and Therapeutics • Sep 24, 2007  (Issue 1270)
, myelodysplastic syndrome and acute leukemia. A minority of patients eventually lose the PNH clone. 1 ...
Eculizumab (Soliris - Alexion) has been approved by the FDA for reduction of hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare form of hemolytic anemia. A recombinant humanized monoclonal antibody, eculizumab is the first drug to be marketed for this indication.
Med Lett Drugs Ther. 2007 Sep 24;49(1270):79-80 |  Show IntroductionHide Introduction

Tetrabenazine (Xenazine) for Huntington's Chorea

   
The Medical Letter on Drugs and Therapeutics • Jan 26, 2009  (Issue 1304)
of schizophrenia, 1 was recently approved by the FDA for the treatment of chorea associated with Huntington’s ...
Tetrabenazine (Xenazine - Ovation Pharmaceuticals), an old drug first synthesized 50 years ago for treatment of schizophrenia, was recently approved by the FDA for the treatment of chorea associated with Huntington's disease. It has been available in other countries for decades.
Med Lett Drugs Ther. 2009 Jan 26;51(1304):7-8 |  Show IntroductionHide Introduction

Addendum: Timing of Levothyroxine

   
The Medical Letter on Drugs and Therapeutics • Feb 01, 2016  (Issue 1487)
The Medical Letter® on Drugs and Therapeutics Volume 58 (Issue 1487) February 1, 2016 Published ...
In our October 26, 2015 article on drugs for hypothyroidism (Med Lett Drugs Ther 2015; 57:147), we said that levothyroxine should be taken on an empty stomach with a full glass of water 30-60 minutes (60 is preferable) before breakfast. We should have added that taking the drug consistently at bedtime, at least 3 hours after the last meal, is an alternative that some patients may find more convenient.
Med Lett Drugs Ther. 2016 Feb 1;58(1487):18 |  Show IntroductionHide Introduction

Erythropoietin For Anemia

   
The Medical Letter on Drugs and Therapeutics • Sep 22, 1989  (Issue 801)
— Unpublished studies reported by the manufacturer in which epoetin was given to more than 1,000 patients ...
Production of erythropoietin, a glycoprotein hormone secreted mainly by the kidney, is often low in patients with chronic renal failure (JW Eschbach, Kidney Int, 35:134, 1989). The US Food and Drug Administration recently approved marketing of epoetin alfa (Epogen - Amgen), a recombinant human erythropoietin, for treatment of anemia in such patients. Epoetin is commercially available in Europe as Eprex (Ortho), and Eprex is available from Ortho in the USA on an investigational basis for treatment of anemia related to AIDS. Epogen and Eprex are chemically...
Med Lett Drugs Ther. 1989 Sep 22;31(801):85-6 |  Show IntroductionHide Introduction

Lamotrigine For Epilepsy

   
The Medical Letter on Drugs and Therapeutics • Mar 17, 1995  (Issue 944)
from the gastrointestinal tract, either with or without food. Plasma concentrations reach a peak in 1.5 to 5 hours. Unlike ...
Lamotrigine (la mo tri jeen; Lamictal - Burroughs Wellcome), a phenyltriazine derivative, has been approved by the US Food and Drug Administration for use in addition to other antiepileptic drugs in adults with partial seizures. Since this diagnostic category includes the largest number of patients with intractable epilepsy, new drugs with antiepileptic activity are usually tried first for this indication. Lamotrigine was first marketed abroad in 1990 and is now available in more than 50 other countries.
Med Lett Drugs Ther. 1995 Mar 17;37(944):21-3 |  Show IntroductionHide Introduction

Nefazodone for Depression

   
The Medical Letter on Drugs and Therapeutics • Apr 14, 1995  (Issue 946)
) and norepinephrine and also acts as an antagonist at alpha 1 -adrenergic and 5-HT 2 receptors (R Fontaine, Clin ...
Nefazodone (Serzone - Bristol-Myers Squibb) was recently approved by the US Food and Drug Administration for treatment of depression. A phenylpiperazine, nefazodone is chemically related to trazodone (Desyrel, and others).
Med Lett Drugs Ther. 1995 Apr 14;37(946):33-5 |  Show IntroductionHide Introduction

Zafirlukast for Asthma

   
The Medical Letter on Drugs and Therapeutics • Dec 20, 1996  (Issue 990)
corticosteroids to decrease the airway inflammation found in patients with chronic asthma (Medical Letter, 37:1 ...
Zafirlukast (za fir loo kast; Accolate - Zeneca), the first leukotriene receptor anta-gonist approved by the US Food and Drug Administration, is now being heavily promoted for oral maintenance treatment of chronic asthma in patients more than 12 years old. It is not recommended for treatment of acute asthma.
Med Lett Drugs Ther. 1996 Dec 20;38(990):111-2 |  Show IntroductionHide Introduction